Electric Therapy Traction Table Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
Sarcopenia Treatment Market by Treatment (Protein Supplements, Vitamin B12 Supplements, Vitamin D & Calcium Supplements and Others), Route of Administration (Oral, Parenteral, and Enteral), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies: Global Opportunity Analysis and Industry Forecast, 2021-2030
- AMR ID : 7-20940
- CAT ID : 7
- Pages : 150
- Date : Oct 2023
Sarcopenia Treatment Market Overview
The global sarcopenia treatment market size was valued at $2,577 million in 2020, and is projected to reach $4,704 million by 2030, registering a CAGR of 6.1% from 2021 to 2030. Sarcopenia is defined as the loss of skeletal muscle mass or flesh as a result of aging. Sarcopenia is characterized by a reduction in muscular size, relative weakness, lack of stamina, difficulty mounting stairs, and poor balance. Exercise level, co-morbidities, nutrition, and other factors all influence the rate of muscle loss. Sarcopenia can result in worse quality of life as well as disability. It refers to the loss of muscle mass and strength that occurs as a result of the normal aging process. Symptoms of sarcopenia include decrease in muscle size, weakness, loss of endurance, trouble in climbing stairs and poor balance.
In developing and poor countries, micronutrient-rich food is consumed in low amounts, resulting in malnutrition. Sarcopenia is caused primarily by malnutrition or vitamin D and vitamin B12 deficiency, which is common among vegetarians and the elderly. As a result, there is no recognized treatment for sarcopenia; nevertheless, proper nutrition and dietary supplements can help with the condition. Nutrition keeps energy levels up and preventing accelerated muscle loss during periods of muscle inactivity. Proteins, amino acids, omega 3 acid, creatine, vitamin D and B12, and calcium carbonate are some of the most significant supplements for simply treating sarcopenia.
The global sarcopenia treatment market has been driven by factors such as rise in the incidence of the elderly population and the growing acceptance of vitamins and dietary supplements. For instance, according to the World Health Organization, by 2050, the world’s population aged 60 years and above is expected reach 2 billion from 900 million in 2015. Furthermore, increase in the cases of sarcopenia is further anticipated to propel the growth of the sarcopenia treatment market. Also, the increase in R&D activities for the treatment of sarcopenia is further estimated to boost the growth of the sarcopenia treatment market. On the other hand, the high-cost of protein supplements and lack of awareness are expected to hamper the market growth during the forecast period.
Moreover, increase in malnutrition and vitamin deficiency in developing countries and increasing per capita healthcare expenditure are expected to drive demand for sarcopenia treatment supplements. In addition, rise in cases of malnutrition because of poor nutritional intake will further provide potential opportunities for the growth of the sarcopenia treatment market in the coming years. However, rise in price of protein supplement and the inaccessibility of sarcopenia treatment drugs is expected to further challenge the growth of the sarcopenia treatment market in the near future.
The impact of COVID-19 pandemic is expected to remain positive for the sarcopenia treatment market. As sarcopenia patients are more vulnerable to COVID-19 infection, which cause systematic inflammation that results into loss of skeletal muscle. Furthermore, in older persons, the need for social isolation during the COVID-19 pandemic has led to protein deficiency and decrease in daily physical activity, which accelerates the loss of muscle strength and function. Persons with diagnosed COVID-19 are also expected to have 2 or 3 weeks of decreased physical functions resulting in secondary sarcopenia. This led to increase in demand for protein supplements that promotes the muscle growth and increases muscle strength. In addition, people who are physically isolated should be given recommendations to do daily exercises such as the ViviFrail graded exercise set, which is primary treatment for sarcopenia. Thus, such factors have impacted the market growth positively in COVID-19.
Sarcopenia Treatment Market Segmentation
The global sarcopenia treatment market is classified on the basis of treatment, route of administration, distribution channel, and region. By treatment, the market is divided into vitamin B12 supplement, Vitamin D & Calcium supplement, protein supplements and others. By route of administration, the market is segmented into oral, parenteral, and enteral. The oral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. The parenteral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The enteral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. By distribution channel, it is categorized hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. By region, the market is analyzed across, North America, Europe, Asia-Pacific and LAMEA.
Treatment segment review
By treatment, the protein supplements segment was the major revenue contributor, and is projected to grow significantly during the forecast period, owing to increase in the prevalence of malnutrition deficiency across the globe.
Sarcopenia Treatment Market
By Treatment
Protien Supplements segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Route of administration segment review
Based on route of administration, the oral segment was the major revenue contributor, and is projected to grow significantly during the forecast period, owing to increase in number of people suffering from chronic conditions such as cancer and diabetes coupled with rise in geriatric population base, is expected to drive the market during the forecast timeframe.
Sarcopenia Treatment Market
By Route Of Administration
Oral Segment hold the dominant position and would continue to maintain the lead over the forecast period.
Get more information on this report : Request Sample Pages
Distribution Channel segment review
Based on distribution channel, the hospital pharmacies segment was the major revenue contributor, and is projected to grow significantly during the forecast period, due to a huge customer base, increase in healthcare expenditure, rise in disease incidence, and the presence of supportive regulatory systems are the key factors anticipating the growth of the market.
Sarcopenia Treatment Market
By Distribution Channel
Hospital Pharmacies segements holds a dominant position in 2020 and continue to maintain lead in the forecast year
Get more information on this report : Request Sample Pages
Region segment review
By region, Asia-Pacific accounted for the largest share in 2020, and is anticipated to maintain its dominance from 2020 to 2030, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region.
The key market players profiled in the sarcopenia treatment market include Abbott laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKline plc., Nestle S.A., Pfizer, Inc. Novartis AG, Sanofi, Inc., Zydus Cadila, Ltd. and F-Hoffmann La-Roche.
Sarcopenia Treatment Market
By Region
2030
Asia-pacific
North America
Europe
LAMEA
Asia Pacific region holds the dominant position in 2020 and would exhibit the highest CAGR of 7.5% during 2021-2030
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the sterilization services market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers sarcopenia treatment market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global sarcopenia treatment market growth.
Key Market Segments
By Treatment
- Protein Supplements
- Vitamin B12 Supplements
- Vitamin D & Calcium Supplements
- Others
By Route of Administration
- Oral
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Parenteral
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Enteral
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Abbott laboratories, Inc.
- American Way (Amway) Corporation
- Bayer AG
- GlaxoSmithKline plc.
- Nestle S.A.
- Pfizer, Inc.
- Novartis AG
- Sanofi, Inc.
- Zydus Cadila, Ltd
- F-Hoffmann La-Roche
Sarcopenia Treatment Market Report Highlights
| Aspects | Details |
|---|---|
| By TREATMENT |
|
| By ROUTE OF ADMINISTRATION |
|
| By DISTRIBUTION CHANNEL |
|
| By Region |
|
| Key Market Players | PFIZER INC., ABBOTT LABORATORIES, INC, NESTLÉ S.A., Bayer AG, F. HOFFMANN-LA ROCHE LTD., American Way (Amway)Corporation, Novartis AG, SANOFI INC., GlaxoSmithKline plc, Zydus Cadilla, Ltd |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top players positioning, 2020
3.3.Porter’s five force analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Surge in geriatric Population
3.4.1.2.Increase in initiatives by government and private organizations for sarcopenia treatment
3.4.2.Restraint
3.4.2.1.Lack of effective therapies for sarcopenia
3.4.3.Opportunities
3.4.3.1.Increase in the adoption of supplements
3.4.3.2.Increase in malnutrition and Vitamin Deficiency in developing countries
3.4.4.Impact analysis
3.5.COVID-19 impact on the global sarcopenia treatment market
CHAPTER 4:SARCOPENIA TREATMENT MARKET, BY TREATMENT
4.1.Overview
4.1.1.Market size and forecast, by product
4.2.Protein supplements
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Vitamin B-12 supplements
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Vitamin D & calcium supplements
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1.Overview
5.1.1.Market size and forecast, by route of administration
5.2.Oral
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by distribution channel
5.3.Parenteral
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by distribution channel
5.4.Enteral
5.4.1.Market size and forecast by region
5.4.2.Market analysis, by country
5.4.3.Market size and forecast, by distribution channel
CHAPTER 6:SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast, by distribution channel
6.2.Hospital- pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug stores & retail pharmacy
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online Pharmacy
6.4.1.Market size and forecast , by region
6.4.2.Market analysis, by country
CHAPTER 7:SARCOPENIA TREATMENT MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast, by region
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. sarcopenia treatment market, by treatment
7.2.2.1.2.U.S sarcopenia treatment market, by route of administration
7.2.2.1.3.U.S. sarcopenia treatment market, by distribution channel
7.2.2.2.Canada
7.2.2.2.1.Canada sarcopenia treatment market, by disease
7.2.2.2.2.Canada sarcopenia treatment market, by route of administration
7.2.2.2.3.Canada sarcopenia treatment market, by distribution channel
7.2.2.3.Mexico
7.2.2.3.1.Mexico sarcopenia treatment market, by treatment
7.2.2.3.2.Mexico sarcopenia treatment market, by route of administration
7.2.2.3.3.Mexico sarcopenia treatment market by distribution channel
7.2.3.North America market size and forecast, by treatment
7.2.4.North America market size and forecast, by route of administration
7.2.5.North America market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany sarcopenia treatment market, by disease
7.3.2.1.2.Germany sarcopenia treatment market, by route of administration
7.3.2.1.3.Germany sarcopenia treatment market, by distribution channel
7.3.2.2.France
7.3.2.2.1.France sarcopenia treatment market, by treatment
7.3.2.2.2.France sarcopenia treatment market, by route of administration
7.3.2.2.3.France sarcopenia treatment market, by distribution channel
7.3.2.3.UK
7.3.2.3.1.UK sarcopenia treatment market, by treatment
7.3.2.3.2.UK sarcopenia treatment market, by route of administration
7.3.2.3.3.UK sarcopenia treatment market, by distribution channel
7.3.2.4.Italy
7.3.2.4.1.Italy sarcopenia treatment market, by treatment
7.3.2.4.2.Italy sarcopenia treatment market, by route of administration
7.3.2.4.3.Italy sarcopenia treatment market, by distribution channel
7.3.2.5.Spain
7.3.2.5.1.Spain sarcopenia treatment market, by treatment
7.3.2.5.2.Spain sarcopenia treatment market, by route of administration
7.3.2.5.3.Spain sarcopenia treatment market, by distribution channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe sarcopenia treatment market, by treatment
7.3.2.6.2.Rest of Europe sarcopenia treatment market, by route of administration
7.3.2.6.3.Rest of Europe sarcopenia treatment market, by distribution channel
7.3.3.Europe market size and forecast, by treatment
7.3.4.Europe market size and forecast, by route of administration
7.3.5.Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan sarcopenia treatment market, by treatment
7.4.2.1.2.Japan sarcopenia treatment market, by route of administration
7.4.2.1.3.Japan sarcopenia treatment market, by distribution channel
7.4.2.2.China
7.4.2.2.1.China sarcopenia treatment market, by treatment
7.4.2.2.2.China sarcopenia treatment market, by route of administration
7.4.2.2.3.China sarcopenia treatment market, by distribution channel
7.4.2.3.Australia
7.4.2.3.1.Australia sarcopenia treatment market, by treatment
7.4.2.3.2.Australia sarcopenia treatment market, by route of administration
7.4.2.3.3.Australia sarcopenia treatment market, by distribution channel
7.4.2.4.India
7.4.2.4.1.India sarcopenia treatment market, by treatment
7.4.2.4.2.India sarcopenia treatment market, by route of administration
7.4.2.4.3.India sarcopenia treatment market, by distribution channel
7.4.2.5.South Korea
7.4.2.5.1.South Korea sarcopenia treatment market, by treatment
7.4.2.5.2.South Korea sarcopenia treatment market, by route of administration
7.4.2.5.3.South Korea sarcopenia treatment market, by distribution channel
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific sarcopenia treatment market, by treatment
7.4.2.6.2.Rest of Asia-Pacific sarcopenia treatment market, by route of administration
7.4.2.6.3.Rest of Asia-Pacific sarcopenia treatment market, by distribution channel
7.4.3.Asia-Pacific market size and forecast, by treatment
7.4.4.Asia-Pacific market size and forecast, by route of administration
7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil sarcopenia treatment market, by treatment
7.5.2.1.2.Brazil sarcopenia treatment market, by route of administration
7.5.2.1.3.Brazil sarcopenia treatment market, by distribution channel
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia sarcopenia treatment market, by treatment
7.5.2.2.2.Saudi Arabia sarcopenia treatment market, by route of administration
7.5.2.2.3.Saudi Arabia sarcopenia treatment market, by distribution channel
7.5.2.3.South Africa
7.5.2.3.1.South Africa sarcopenia treatment market, by treatment
7.5.2.3.2.South Africa sarcopenia treatment market, by route of administration
7.5.2.3.3.South Africa sarcopenia treatment market, by distribution channel
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA sarcopenia treatment market, by treatment
7.5.2.4.2.Rest of LAMEA sarcopenia treatment market, by route of administration
7.5.2.4.3.Rest of LAMEA sarcopenia treatment market, by distribution channel
7.5.3.LAMEA market size and forecast, by treatment
7.5.4.LAMEA market size and forecast, by route of administration
7.5.5.LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES, INC
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.American Way (Amway)Corporation
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.3.Bayer AG
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.F. HOFFMANN-LA ROCHE LTD.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.GlaxoSmithKline plc
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.NESTLÉ S.A.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Novartis AG
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Business performance
8.8.PFIZER INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.SANOFI INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Zydus Cadilla, Ltd
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.1.Business performance
LIST OF TABLES
TABLE 01.GLOBAL SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 02.SARCOPENIA TREATMENT MARKET FOR PROTIENS SUPPLEMENTS, BY REGION, 2020–2030 ($MILLION)
TABLE 03.SARCOPENIA TREATMENT MARKET FOR VITAMIN B12 SUPPLEMENT, BY REGION, 2020–2030 ($MILLION)
TABLE 04.SARCOPENIA TREATMENT MARKET FOR VITAMIN D & CALCIUM SUPPLEMENTS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.SARCOPENIA TREATMENT MARKETFOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 07.SARCOPENIA TREATMENT MARKET FOR ORAL, BY REGION, 2020–2030 ($MILLION)
TABLE 08.SARCOPENIA TREATMENT MARKET FOR ORAL, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 09.SARCOPENIA TREATMENT MARKETFOR PARENTERAL ADMINISTRATION, BY REGION, 2020–2030 ($MILLION)
TABLE 10.PARENTERAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 11.SARCOPENIA TREATMENT MARKETFOR ENTERAL, BY REGION, 2020–2030 ($MILLION)
TABLE 12.SARCOPENIA TREATMENT MARKET FOR ENTERAL, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 13.GLOBAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 14.HOSPITAL-BASED PHARMACIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 15.SARCOPENIA TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 16.SARCOPENIA TREATMENT MARKETFOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 17.GLOBAL SARCOPENIA TREATMENT MARKETGLOBAL, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19.U.S. SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 20.U.S. SARCOPENIA TREATMENT MARKET, BYROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 21.U.S. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 22.. CANADA. SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 23.CANADA SARCOPENIA TREATMENT MARKET, BYROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 24.CANADA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 25.MEXICO SARCOPENIA TREATMENT MARKET, TREATMENT, 2020–2030 ($MILLION)
TABLE 26.MEXICO SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 27.MEXICO SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 28.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 29.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 30.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION, CHANNEL 2020–2030 ($MILLION)
TABLE 31.EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 32.GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 33.GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 34.GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 35.FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 36.FRANCE L SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 37.FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 38.UK SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 39.UK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 40.UK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 41.ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 42.ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 43.ITALY L SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 44.SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 45.SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 46.SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 48.REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 50.EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 51.EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 52.EUROPE G SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 55.JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 56.JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 57.CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 58.CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 59.CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 63.INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 64.INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 65.INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 67.SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 72.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 73.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 74.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 75.LAMEA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 76.BRAZIL SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 77.BRAZIL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 78.BRAZIL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 80.SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 83.SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 86.REST OF LAMEA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 88.LAMEA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 89.LAMEA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 90.LAMEA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 91.ABBOTT: COMPANY SNAPSHOT
TABLE 92.ABBOTT: OPERATING SEGMENTS
TABLE 93.ABBOTT: PRODUCT PORTFOLIO
TABLE 94.AMWAY: COMPANY SNAPSHOT
TABLE 95.AMWAY: OPERATING BUSINESS SEGMENTS
TABLE 96.AMWAY: PRODUCT PORTFOLIO
TABLE 97.BAYER: COMPANY SNAPSHOT
TABLE 98.BAYER: OPERATING SEGMENTS
TABLE 99.BAYER: PRODUCT PORTFOLIO
TABLE 100.ROCHE: COMPANY SNAPSHOT
TABLE 101.ROCHE: OPERATING SEGMENTS
TABLE 102.ROCHE: PRODUCT PORTFOLIO
TABLE 103.GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 104.GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 105.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 106.NESTLÉ: COMPANY SNAPSHOT
TABLE 107.NESTLÉ: OPERATING SEGMENTS
TABLE 108.NESTLÉ: PRODUCT PORTFOLIO
TABLE 109.NOVARTIS: COMPANY SNAPSHOT
TABLE 110.NOVARTIS: OPERATING SEGMENTS
TABLE 111.NOVARTIS: PRODUCT PORTFOLIO
TABLE 112.PFIZER: COMPANY SNAPSHOT
TABLE 113.PFIZER: OPERATING SEGMENTS
TABLE 114.PFIZER: PRODUCT PORTFOLIO
TABLE 115.SANOFI: COMPANY SNAPSHOT
TABLE 116.SANOFI: OPERATING SEGMENTS
TABLE 117.SANOFI: PRODUCT PORTFOLIO
TABLE 118.ZYDUS: COMPANY SNAPSHOT
TABLE 119.ZYDUS: OPERATING SEGMENTS
TABLE 120.ZYDUS: PRODUCT PORTFOLIO
TABLE OF FIGURES
FIGURE 01.GLOBAL SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP PLYAERS POSITIONING, 2020
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06.MODERATE THREAT OF SUBSTITUTION
FIGURE 07.MODERATE THREAT OF NEW ENTRANT
FIGURE 08.HIGH COMPETITIVE RIVALRY
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKET FOR PROTEIN SUPPLEMENTS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKETFOR VITAMIN B12 SUPPLEMENT, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKET FOR VITAMIN D& CALCIUM SUPPLEMENTS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF I SARCOPENIA TREATMENT MARKETFOR OTHERS, MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKETFOR ORALN, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKET FOR PARENTERAL ADMINISTRATION, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKETFOR ENTERAL, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKETFOR HOSPITAL-BASED PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKETFOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF SARCOPENIA TREATMENT MARKETFOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 21.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 22.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 23.BAYER: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 25.BAYER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.GLAXOSMITHKLINE: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.GLAXOSMITHKLINE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 32.NET SALES, 2019–2020 ($MILLION)
FIGURE 33.NESTLÉ: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.NESTLÉ: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.PFIZER NET SALES, 2019–2020 ($MILLION)
FIGURE 39.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 41.SANOFI NET SALES, 2019–2020 ($MILLION)
FIGURE 42.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.SANOFI: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 44.ZYDUS NET SALES, 2019–2020 ($MILLION)
FIGURE 45.ZYDUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46.ZYDUS: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
LED Light-Up Blanket Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 116 |
Pelvic Floor Functional Magnetic Stimulator Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Multi-Modality Biofeedback System Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
High Frequency Evaluation and Therapy Device Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Choose License Type
Why Choose Us ?
24/7 Research support
Quality assurance
Information security
The report efficiently evaluates the market from various dimensions to deliver an
end-product that is informative, elaborate, and accurate and includes detailed
market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast.
The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of
xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the
industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market
opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE
analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing
initiatives, pricing analysis, competitive landscape which help businesses in
decision making. The analysis data is based on current and historical market trends
which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any
organization to gain insight into specific business sector, aligned with specific area
of interest. Thus, SMI offers more accurate, pragmatic, and actionable information
specifically tailored to suit your business needs.
